SIC
KROS icon

SJS Investment Consulting’s Keros Therapeutics KROS Stock Holding History

SJS Investment Consulting’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$621 Buy
58
+50
+625% +$557 ﹤0.01% 2195
2026
Q1 		$89 Buy
8
+4
+100% +$62 ﹤0.01% 2156
2025
Q4 		$82 Buy
+4
New +$70 ﹤0.01% 1969

Other funds holding KROS

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

SJS Investment Consulting's KROS Position: Q2 2026 in Review

SJS Investment Consulting increased its Keros Therapeutics (KROS) stake by 625% in Q2 2026, buying an estimated $557 and bringing the position to 58 shares worth $621. The position accounts for ﹤0.01% of the portfolio, ranked #2195.

SJS Investment Consulting first reported a position in KROS in Q4 2025 and has held it in 3 quarters since. 19 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • SJS Investment Consulting held 58 shares of Keros Therapeutics worth $621 as of Q2 2026.
  • SJS Investment Consulting bought 50 Keros Therapeutics shares in Q2 2026, an estimated $557.
  • Keros Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2195 holding.
  • SJS Investment Consulting first reported a position in Keros Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 19 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.